×
About 11,517,692 results

Joint GI society message: COVID-19 clinical insights for our community of gastroenterologists and gastroenterology care providers
https://gastro.org/press-releases/joint-gi-society-message-covid-19-clinical-insights-for-our-community-of-gastroenterologists-and-gastroenterology-care-providers/

The situation involving the COVID-19 pandemic continues to evolve. There is recent evidence suggesting the potential for coronavirus transmission through droplets and perhaps fecal shedding1,2 posing potential risks during endoscopy and colonoscopy to other patients, endoscopy personnel and ourselves. We provide below important information as well as recommendations to consider in your insti...

Coronavirus (COVID-19) Resources
https://www.aafp.org/journals/afp/explore/COVID-19.html

AAFP & AFP curated list of resources.

Impact of Superspreaders on dissemination and mitigation of COVID-19
https://www.medrxiv.org/content/10.1101/2020.05.17.20104745v3

The severity of the Covid-19 pandemic has led to the use of extreme control measures which has halted the spread, but at enormous socioeconomic cost. We set out to explore whether a model that includes 'superspreader' could explain aspects of mitigation strategies that explain the dramatic effect. Methods: We developed an age structured agent-based model that includes persons who spread the dis...

Super-spreading events and contribution to transmission of MERS, SARS, and SARS-CoV-2 (COVID-19)
https://www.journalofhospitalinfection.com/article/S0195-6701(20)30177-8/fulltext

There is no clear definition for the term ‘super-spreader’ or ‘super-spreading event’. The World Health Organization refers to a super-spreader as a patient (or an event) that may transmit infection to a larger number of individuals than is usual by one individual (or event). In the severe acute respiratory syndrome (SARS) situation, a super-spreading event was defined as the transmission of SA...

Re-Opening the Economy and Getting Back to Business: Business Owners’ Liability Risk When Dealing With Customers and Others
https://www.natlawreview.com/article/re-opening-economy-and-getting-back-to-business-business-owners-liability-risk-when

While the “right” time to open the economy is hotly debated, many states have made the decision that it is time to get back to business. That means that businesses will be opening while there is still a continuing risk of COVID-19 exposure. As long as the risk of exposure remains, businesses face potential liability when they allow customers, vendors, and other parties to enter their premises...

Copper Won’t Save You From Coronavirus
https://www.nytimes.com/article/copper-coronavirus-masks.html?algo=identity&fellback=false&imp_id=973064323&action=click&module=Science Technology&pgtype=Homepage

Pandemic fears have created interest in metallic products touting antimicrobial properties. But experts have doubts about the copper craze.

Why copper could help prevent future pandemic, and what it does to coronavirus
https://www.cleveland.com/news/2020/03/why-copper-could-help-prevent-future-pandemic-and-what-it-does-to-coronavirus.html

A recent clinical study that indicates copper is far better than other common materials at preventing the spread of infectious diseases has caught the public’s attention amid the ongoing coronavirus pandemic.

Why do some COVID-19 patients infect many others, whereas most don’t spread the virus at all?
https://www.sciencemag.org/news/2020/05/why-do-some-covid-19-patients-infect-many-others-whereas-most-don-t-spread-virus-all?fbclid=IwAR3SK1b

Business Beware: Premise Liability in the Age of the COVID-19 Economic Restart
https://www.jdsupra.com/legalnews/business-beware-premise-liability-in-97643

MHTC Guide to Safely Returning to Work
http://www.mhtc.org/wp-content/uploads/2020/05/MHTC-COVID-19-Briefing-v33-5.13.20.pdf

State Guidance on Elective Surgeries
https://www.ascassociation.org/asca/resourcecenter/latestnewsresourcecenter/covid-19/covid-19-state

consider stopping elective procedures amid the COVID-19 outbreak. On March 18, the Centers for Medicare & Medicaid Services (CMS) also released guidance to limit "non-essential adult elective surgery and medical and surgical procedures, including all dental procedures." The guidance additionally notes that while "decisions remain the responsibility of local healthcare delivery systems...and tho...

Non-Emergent, Elective Medical Services, and Treatment Recommendations
https://www.cms.gov/files/document/cms-non-emergent-elective-medical-recommendations.pdf

To aggressively address COVID-19, CMS recognizes that conservation of critical healthcare resources is essential, in addition to limiting exposure of patients and staff to the virus that causes COVID-19. CMS also recognizes the importance of reducing burdens on the existing health system and maintaining services while keeping patients and providers safe. CMS, in collaboration with medical s...

COVID Interactive Primer
https://interactives.nejm.org/external/covid_simulation/index.html

This educational primer is meant to introduce new internal medicine interns and other providers to some of the basic concepts of managing floor patients suspected or confirmed of having COVID-19.

Covid-19 makes us face the hazy line between ‘elective’ and ‘essential’ medicine
https://www.washingtonpost.com/outlook/coronavirus-elective-essential-medicine/2020/06/18/d1942ea2-af1e-11ea-8758-bfd1d045525a_story.html

Covid-19 Rx: Treatment Simulations
https://covid19rx.nejm.org/landing/index.html?query=C19&cid=DM94109_JW_Registered_Users_and_InActive&bid=219058013

CDA Position Statement on Coronavirus (COVID-19) Pandemic
https://www.copper.org/applications/antimicrobial/COVID-19.html

In response to the COVID-19 pandemic, Copper Development Association (CDA) developed the following position statement to address an influx of inquiries from the media and external stakeholders.

Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis
https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16725

Cerebral involvement in COVID-19 is associated with metabolic and coagulation derangements: an EEG study
https://link.springer.com/article/10.1007/s00415-020-09958-2

Association between high serum total cortisol concentrations and mortality from COVID-19
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30216-3/fulltext

American Heart Association Hypertension Guideline Toolkit
http://aha-clinical-review.ascendeventmedia.com/books/aha-high-blood-pressure-toolkit/
American Heart Association

AHA High Blood Pressure Toolkit

An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
https://stories.gilead.com/articles/an-open-letter-from-daniel-oday-june-22

After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently give...

Association of Circadian Abnormalities in Older Adults With an Increased Risk of Developing Parkinson Disease
https://jamanetwork.com/journals/jamaneurology/article-abstract/2767087

Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19
https://www.rheumatology.org/Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-MIS-C-Hyperinflammation.pdf

COVID-19 Clinical Guidance for Pediatric Patients with Rheumatic Disease
https://www.rheumatology.org/Portals/0/Files/COVID-19-Clinical-Guidance-Summary-for-Pediatric-Patients-with-Rheumatic-Disease.pdf

COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications
https://link.springer.com/content/pdf/10.1007/s12020-020-02325-1.pdf

Managing common endocrine disorders amid COVID-19 pandemic
https://www.sciencedirect.com/science/article/pii/S1871402120301697

Determinants of COVID-19 disease severity in patients with cancer
https://www.nature.com/articles/s41591-020-0979-0

Antibody Detection and Dynamic Characteristics in Patients with COVID-19
https://watermark.silverchair.com/ciaa461.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAABEYwggRCBgkqhkiG9w0BBwagggQzMIIELwIBADCCBCgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQML-2UYyGMp5__74HZAgEQgIID-VP47852zLLsLFFHC7k2obWGvI27loF7mFx6ccaQRjbwhuQIGLnPxwfOQMeFlfFVAFZAKa4ln4Zu8tJ4pyMAe_0DpNoBtNd7J4G248ZywRygT0RWAeDM9E0oxYYaVyNIeQYIseOEQYJljSdOjlMeT7rTXn_bjWG0XgnM4hcKG5vdzeeNaCMClYAUcNlvEL_JhqOEsouWaE1P2B6rwqyTQFevO_P6IUOHYMipr0kA7hT7Ei4R5HE-BRVNatcJs-QWZFqwXdbArSLOVckkOr84O73LZ9FLbR5nLxG59zI_JfXk_xBxRbftrCAY82kgfXjxdLd6WtGY-zDY52Y_gWhhwd3JZ9gZaBX9zxT_0V9epseHguRBD3_DNexdrwZ2RhzcN6GxeRTnJORFqFEB-0haDPa3s7zgZtQJtEzYGzo3380CI2d0J1GZeI8tZNGHhwvdKAxrpqb6oSYjIH41u6eLPgQwoyg6DAJISSL8pfDZWcc5ILKQYGy4HMlL9PqKv2J8Py1NaFNHiTPFlPN6VbRBGUxT_dWyspgerDc3V6bD2Spr6Q68vQEgz1L4eF9DOWDLKrCmBC00e2m7kMAGQ9PXPGalQBCNClMflQvj4s4itOfBrdOxfMgRb2jeVcK0wv28oBg0L4a1mxhUbBb6vVY4AqAwBgMaxZxxHxyBfRJBdWr3bk3S8ow5-UAFEXFxMwShRR3Wp5wxiZ5kv_hs4ZW8ycXC-Lc77qCSHqpgGl3qFJsakyjlalhF1AUMNo7Suj6HtWtYUKiQHe3hgZiFI6T9Up8hIhYPkoQNKd3v5jmzZl0YF7oEeqrOVoD6mOC5tRBnY1EE1eS53CHCCuCpxwEkES6BWHb-P0YzfM4SSpQlNCXZUxxHXnlmWZoNz9KVqXL-zm6x7dlG7Qd-hjsFoN4wn8h_THDZh3XgbL2CGCnKkRVBYJuMhz7iavKFHzogXUfP0U9zGcYLYS1wDBvTrkEU94n3sHbZejRFqQ14dVg-A3cep6o4d8H8p5mw1AvkSzp-s-NR2tjiJ66nTR9v_urbFGMSnlfo8lk5HH3DtZUG1KHCx0Lp626rmX0IXV2SxetMQCV7AXLRHmG-xa_67N74Lmkiqho2p6RkYiKtrkTZ-6h8ykKhwa0DfdbB1FrDRADlwOk8CnaUfNeiWtw82AoyQjWP6BMkIxgm-mZ3hV7heeH0RB73ES7OLUR2C1R2hyyt21cSo2Ub0jugp9-Gk5asCWsi8XKK7bubNP3D7vD0N2VdLkO1ZT969XyveN0soj5BYAbe7XMzPuf8dA8JfX86duPXjnnPG4qrvRS2NhaObrb-M_t5xa2VxIlTYcXNlnmTpkV7VnSyTqki_w

The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the COVID-19. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.

Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
https://www.nejm.org/doi/full/10.1056/NEJMc070348
The New England Journal of Medicine;

Previous studies have demonstrated that IgG and neutralizing antibodies against coronavirus associated with the severe acute respiratory syndrome (SARS) may persist, in spite of a decline in titer, for 2 years in patients who have recovered from SARS.

Emergency Restraining Order and Injunctive Relief against Landmark Hospital of Athens
https://img.medscapestatic.com/article/932/722/20-06-17-Landmark-_COMP_FSC.pdf

This action seeks immediate court intervention to stop Defendant Landmark Hospital from concealing and mishandling a COVID-19 outbreak in their facility, and to prevent Defendant Landmark from receiving patients into their facility or discharging or transferring patients out of their facility.

Hospitals won't release number of workers with COVID-19; nurses union urges transparency
https://www.10tv.com/article/news/local/hospitals-wont-release-number-workers-covid-19-nurses-union-urges-transparency-2020-apr/530-39d6033b-9ec9-4ea4-8307-3f90e3194c3a

Amid push toward transparency, several Portland-area hospitals won’t disclose coronavirus patient tallies
https://www.oregonlive.com/coronavirus/2020/03/amid-push-toward-transparency-several-portland-area-hospitals-wont-disclose-coronavirus-patient-tallies.html

Fraudulent Coronavirus Disease 2019 (COVID-19) Products
https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-products

The U.S. Food and Drug Administration is issuing warning letters to firms for selling fraudulent products with claims to prevent, treat, mitigate, diagnose or cure coronavirus disease 2019 (COVID-19). We are actively monitoring for any firms marketing products with fraudulent COVID-19 prevention and treatment claims. The FDA is exercising its authority to protect consumers from firms selling un...

There are so many coronavirus myths that even Snopes can’t keep up
https://www.washingtonpost.com/media/2020/04/15/coronavirus-misinformation-snopes/

COVID-19 Myths vs. Realities
https://www.jhsph.edu/covid-19/articles/coronavirus-facts-vs-myths.html

The swiftly moving novel coronavirus continues its relentless spread around the world, upending life as we know it and creating a breeding ground for misinformation. Some rumors are harmless, while others can be dangerous, stoking fear and threatening health. Here, we separate true from false, based on the best science and expertise available.

The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design
https://www.sciencedirect.com/science/article/pii/S1109966620300610

Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colch...

Colchicine as a possible therapeutic option in COVID-19 infection
https://link.springer.com/article/10.1007/s10067-020-05247-5

In contrast, we consider that colchicine can be a good therapeutic option because of several effects in the immunology system involved in SARS-CoV-2 infection and in the acute respiratory distress syndrome (ARDS). Colchicine has effects on the chemotaxis of inflammatory cells such as neutrophils and monocytes and on the intracellular transportation of vesicles such as endosomes and exosomes.

SARS‐CoV‐2 viral spike G614 mutation exhibits higher case fatality rate
https://onlinelibrary.wiley.com/doi/full/10.1111/ijcp.13525
The International Journal of Clinical Practice;

The COVID‐19 pandemic is caused by infection with the SARS‐CoV‐2 virus. The major mutation detected to date in the SARS‐CoV‐2 viral envelope spike protein, which is responsible for virus attachment to the host and is also the main target for host antibodies, is a mutation of an aspartate (D) at position 614 found frequently in Chinese strains to a glycine (G). We sought to infer health impact o...

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
https://www.scripps.edu/_files/pdfs/news-and-events/The D614G mutation in the SARS-CoV-2 spike protein reduces S1.pdf

SARS coronavirus 2 (SARS-CoV-2) isolates encoding a D614G mutation in the viral spike (S) protein predominate over time in locales where it is found, implying that this change enhances viral transmission. We therefore compared the functional properties of the S proteins with aspartic acid (SD614) and glycine (SG614) at residue 614. We observed that retroviruses pseudotyped with SG614 infect...

Mutated coronavirus shows significant boost in infectivity
https://www.scripps.edu/news-and-events/press-room/2020/20200612-choe-farzan-coronavirus-spike-mutation.html

A tiny genetic mutation in the SARS coronavirus 2 variant circulating throughout Europe and the United States significantly increases the virus’ ability to infect cells, lab experiments performed at Scripps Research show.

A silent epidemic
https://news.harvard.edu/gazette/story/2020/04/one-third-of-hospitalized-covid-19-patients-show-signs-of-delirium/
Stephanie Dutchen

Geriatrician Sharon Inouye on the need to combat delirium in COVID-19 patients

This coronavirus mutation has taken over the world. Scientists are trying to understand why.
https://www.washingtonpost.com/science/2020/06/29/coronavirus-mutation-science/?arc404=true

A mutation affecting the virus's spike protein changed amino acid 614 from “D” (aspartic acid) to “G” (glycine). Research suggests that this small change — which affects three identical amino acid chains — might make the spike protein more effective, enhancing the virus’s infectiousness.

Mutation Allows Coronavirus to Infect More Cells, Study Finds. Scientists Urge Caution.
https://www.nytimes.com/2020/06/12/science/coronavirus-mutation-genetics-spike.html

Geneticists said more evidence is needed to determine if a common genetic variation of the virus spreads more easily between people.

Neurologic Features in Severe SARS-CoV-2 Infection
https://www.nejm.org/doi/full/10.1056/NEJMc2008597

We report the neurologic features in an observational series of 58 of 64 consecutive patients admitted to the hospital because of acute respiratory distress syndrome (ARDS) due to Covid-19. The patients received similar evaluations by intensivists in two intensive care units (ICUs) in Strasbourg, France, between March 3 and April 3, 2020.

‘They Want to Kill Me’: Many Covid Patients Have Terrifying Delirium
https://www.nytimes.com/2020/06/28/health/coronavirus-delirium-hallucinations.html

To a startling degree, many coronavirus patients are reporting similar experiences. Called hospital delirium, the phenomenon has previously been seen mostly in a subset of older patients, some of whom already had dementia, and in recent years, hospitals adopted measures to reduce it.

Delirium Incidence, Duration and Severity in Critically Ill Patients with COVID-19
https://www.medrxiv.org/content/10.1101/2020.05.31.20118679v1.full.pdf

Delirium incidence, duration and severity in patients admitted to the intensive care unit (ICU) due to COVID-19 is not known.

Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease
https://www.e-jmd.org/upload/jmd-19082.pdf
Journal of Movement Disorders;

We recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cultural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as normosmia (CCSIT score ≥ 9)...

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon is especially pronounced in patients with Levodopa-induced dyskinesia (LID).

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.

Expert Perspective on ASCO20 Gastrointestinal Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200231/full/

Jul 1st, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 2nd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival with secondary cytoreductive surgery (53.7 months) compared with no surgery (46 months).

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.50991
Annals of Clinical and Translational Neurology;

Feb 6th, 2020 - To investigate whether the burden of white matter hyperintensities (WMHs) is associated with the risk of developing levodopa‐induced dyskinesia (LID) in Parkinson’s disease (PD).

The impact of levodopa therapy-induced complications on quality of life in Parkinson’s disease patients in Singapore
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593098/

The objective of this study was to investigate the impact of levodopa therapy-induced complications on the quality of life (QoL) of Parkinson’s disease (PD) patients in Singapore over a 1-year follow-up period. 274 PD patients were prospectively recruited, of which 78 patients completed the follow-up. Patients were evaluated on: (1) motor symptoms, (2) non-motor symptoms, (3) levodopa therapy-i...

COVID-19 in Racial and Ethnic Minority Groups
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html
CDC

The effects of COVID-19 on the health of racial and ethnic minority groups is still emerging; however, current data suggest a disproportionate burden of illness and death among racial and ethnic minority groups. A recent CDC MMWR report included race and ethnicity data from 580 patients hospitalized with lab-confirmed COVID-19 found that 45% of individuals for whom race or ethnicity data was av...

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30264-3/fulltext
The Lancet Public Health;

The risk of severe COVID-19 if an individual becomes infected is known to be higher in older individuals and those with underlying health conditions. Understanding the number of individuals at increased risk of severe COVID-19 and how this varies between countries should inform the design of possible strategies to shield or vaccinate those at highest risk.

An Oral History of Coronavirus: Testimonies about the pandemic
https://www.washingtonpost.com/graphics/2020/national/coronavirus-oral-history/

An Oral History of COVID-19 From Doctors & Frontline Workers

Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/dr-usmani-on-activity-of-teclistamab-in-relapsed-refractory-multiple-myeloma

May 30th, 2020

Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
https://www.onclive.com/view/robust-data-and-multivariate-analyses-support-cabazitaxel-as-a-standard-of-care-in-mcrpc

May 30th, 2020

Infigratinib Demonstrates Clinical Activity Across Settings in Urothelial Cancer
https://www.onclive.com/view/infigratinib-demonstrates-clinical-activity-across-settings-in-urothelial-cancer

May 31st, 2020

Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC
https://www.onclive.com/view/alectinib-continues-to-maintain-significant-os-benefit-in-emalkem-nsclc

May 30th, 2020

Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC
https://www.onclive.com/view/tepotinib-displays-durable-clinical-benefit-in-metex14altered-nsclc

May 30th, 2020

Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review
https://www.onclive.com/view/pralsetinib-active-across-emretem-tumor-types-and-gains-fda-review-

May 31st, 2020

Dr. Plimack on Updated Findings of the KEYNOTE-426 Study in RCC
https://www.onclive.com/view/dr-plimack-on-updated-findings-of-the-keynote426-study-in-rcc

May 31st, 2020

MGD013 Demonstrates Encouraging Activity Across Tumor Types
https://www.onclive.com/view/mgd013-demonstrates-encouraging-activity-across-tumor-types

May 31st, 2020

TRK Inhibitor Continues to Show Multi-Cancer Effects
https://www.medpagetoday.com/meetingcoverage/asco/86834

Jun 1st, 2020

Early Palliation: Boon for AML Patients on Intensive Chemo
https://www.medpagetoday.com/meetingcoverage/asco/86820

Jun 1st, 2020

Autologous TILs Active in Refractory Melanoma
https://www.medpagetoday.com/meetingcoverage/asco/86840

Jun 1st, 2020

Hydroxychloroquine, Azithromycin Combo Risky for Cancer Patients
https://www.medpagetoday.com/meetingcoverage/ascovideopearls/87062

Jun 14th, 2020

Newly Diagnosed MM: RVd Still Standard of Care
https://www.medpagetoday.com/meetingcoverage/ascovideopearlsmm/87038

Jun 11th, 2020

High Marks for CAR T Cells in R/R Myeloma
https://www.medpagetoday.com/meetingcoverage/asco/86858

Jun 2nd, 2020

Second Surgery Gets OS Win in Recurrent Ovarian Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86836

Jun 1st, 2020

Dr. Gwin on the Mechanism of Action of Alpha-TEA in HER2-Positive Metastatic Breast Cancer
https://www.onclive.com/view/dr-gwin-on-the-mechanism-of-action-of-alphatea-in-her2positive-metastatic-breast-cancer

Jun 4th, 2020

Dr. Mascarenhas on the Impact of Ruxolitinib on the Myelofibrosis Treatment Paradigm
https://www.onclive.com/view/dr-mascarenhas-on-the-impact-of-ruxolitinib-on-the-myelofibrosis-treatment-paradigm

Jun 4th, 2020

Surgery for Metastatic Breast Cancer Fails to Boost Overall Survival
https://www.medpagetoday.com/meetingcoverage/asco/86802

May 31st, 2020

Pembrolizumab May Help in Triple-Negative Breast Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86804

May 31st, 2020

PTSD Symptoms Common in Stem Cell Recipients
https://www.medpagetoday.com/meetingcoverage/asco/86811

May 31st, 2020

Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC
https://www.onclive.com/view/dr-rodriguezabreu-on-updated-results-from-the-keynote189-trial-in-nsclc

Jun 4th, 2020

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC
https://www.onclive.com/view/dr-wolf-on-updated-findings-with-capmatinib-in-metex14mutant-nsclc

Jun 2nd, 2020

COSMIC-021 Data Affirm Activity of Cabozantinib/Atezolizumab in mCRPC
https://www.onclive.com/view/cosmic021-data-affirm-activity-of-cabozantinibatezolizumab-in-mcrpc

Jun 7th, 2020

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma
https://www.onclive.com/view/dr-richardson-on-phase-1-data-with-cc92480-in-multiple-myeloma

May 31st, 2020

Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer
https://www.onclive.com/view/dr-zakashansky-on-the-benefit-of-maintenance-olaparib-in-brca-ovarian-cancer

Jun 1st, 2020

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer
https://www.onclive.com/view/dr-poveda-on-the-results-of-the-solo2-trial-in-ovarian-cancer

May 31st, 2020

CD71-Directed Probody-Drug Conjugate Shows Safety, Signals of Activity in Advanced Solid Tumors
https://www.onclive.com/view/cd71directed-probodydrug-conjugate-shows-safety-signals-of-activity-in-advanced-solid-tumors

Jun 1st, 2020

Pevonedistat/Azacitidine Shows Favorable Activity in Higher-Risk MDS/CMML, Low-Blast AML
https://www.onclive.com/view/pevonedistatazacitidine-shows-favorable-activity-in-higherrisk-mdscmml-lowblast-aml

Jun 2nd, 2020

Addition of Veliparib to Cisplatin Significantly Improves PFS in BRCA-Like Advanced TNBC
https://www.onclive.com/view/addition-of-veliparib-to-cisplatin-significantly-improves-pfs-in-brcalike-advanced-tnbc

Jun 1st, 2020

Dr. Rodriguez-Abreu on the Final Analysis of the KEYNOTE-189 Trial in NSCLC
https://www.onclive.com/view/dr-rodriguezabreu-on-the-final-analysis-of-the-keynote189-trial-in-nsclc

May 31st, 2020

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC
https://www.onclive.com/view/dr-herbst-on-the-benefit-of-adjuvant-osimertinib-in-egfrmutant-nsclc

May 31st, 2020

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL
https://www.onclive.com/view/dr-wang-on-correlative-data-from-the-zuma2-trial-in-mcl

May 31st, 2020

Steroid drug hailed as 'breakthrough' for seriously ill COVID-19 patients
https://www.reuters.com/article/us-health-coronavirus-steroid/steroid-dexamethasone-reduces-deaths-among-patients-with-severe-covid-19-trial-shows-idUSKBN23N1VP

A cheap and widely used steroid called dexamethasone has become the first drug shown to be able to save the lives of COVID-19 patients in what scientists said is a “major breakthrough” in the coronavirus pandemic.

Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204727/

Individuals with Familial Hypercholesterolaemia (FH) are at very high risk of cardiovascular disease, which is associated with poor outcomes from coronavirus infections. COVID-19 puts strain on healthcare systems and may impair access to routine FH services. On behalf of the International Lipid Expert Panel (ILEP) and the European FH Patient Network (FH Europe), we present brief recommendations...

Familial hypercholesterolaemia and COVID‐19: triggering of increased sustained cardiovascular risk
https://onlinelibrary.wiley.com/doi/10.1111/joim.13070

Early data from Wuhan, China, show that patients with COVID‐19 are typically male, aged 40 to 60 years, and about one‐third have comorbidities. Moreover, of 138 COVID‐19 patients hospitalized in Wuhan and treated in an intensive care unit (ICU), 25% had cardiovascular disease and 58% hypertension; the respective figures for non‐ICU‐treated COVID‐19 patients were10% and 22% [1]. Based on these e...

Recovering patient volume and practice finances in the wake of COVID-19: 12 tips
https://www.aafp.org/journals/fpm/blogs/inpractice/entry/recovering_practice_finances.html

Nationally, patient volume has dropped 60%(www.medscape.com) since the start of the pandemic and is now rebounding, either gradually or rapidly depending on local circumstances. However, practices are unlikely to return to normal volumes for some time as patients continue to avoid the office and as offices continue to keep high-risk patients at home and treat them via telehealth. These changes ...

Plasminogen improves lung lesions and hypoxemia in patients with COVID-19
https://academic.oup.com/qjmed/advance-article/doi/10.1093/qjmed/hcaa121/5818885

Lungs from patients with coronavirus disease 2019 (COVID-19) have shown typical signs of acute respiratory distress syndrome (ARDS), formation of hyaline membrane mainly composed of fibrin and ‘ground-glass’ opacity. Previously, we showed plasminogen itself is a key regulator in fibrin degradation, wound healing and infection.

After patient volume collapsed amid the coronavirus pandemic, some see signs of recovery
https://www.hfma.org/topics/news/2020/05/after-patient-volume-collapsed-amid-the-coronavirus--some-see-si.html

Overall patient volumes declined at hospitals by more than 50% amid the coronavirus pandemic. Outpatient volumes may be beginning to turn around as hospitals restart elective procedures. Hospitals face challenges in restarting elective procedures, including staffing, equipment and patient fears. Hospital patient volumes declined steeply in March and April amid mass suspension of elective pro...

People Who Are at Higher Risk for Severe Illness
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html
CDC

COVID-19 is a new disease and there is limited information regarding risk factors for severe disease. Based on currently available information and clinical expertise, older adults and people of any age who have serious underlying medical conditions might be at higher risk for severe illness from COVID-19.

Coronavirus: Physician survey finds patient volumes down, likely to stay down for a year
https://www.medicaleconomics.com/news/coronavirus-physician-survey-finds-patient-volumes-down-likely-stay-down-year

Patient volumes are down for physicians due to the COVID-19 coronavirus pandemic and it is expected they will continue to be down for the next year, according to a new survey from Piper Sandler.

Can a toilet promote virus transmission? From a fluid dynamics perspective
https://aip.scitation.org/doi/10.1063/5.0013318

Currently, a novel coronavirus named “SARS-CoV-2” is spreading rapidly across the world, causing a public health crisis, economic losses, and panic. Fecal–oral transmission is a common transmission route for many viruses, including SARS-CoV-2. Blocking the path of fecal–oral transmission, which occurs commonly in toilet usage, is of fundamental importance in suppressing the spread of viruses. H...

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples
https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(20)30083-2.pdf

We present severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) real-time RT-PCR results of all respiratory and faecal samples from patients with coronavirus disease 2019 (COVID-19) at the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China, throughout the course of their illness and obligated quarantine period.